Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223434

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223434

MEA Acute Myeloid Leukemia Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 253 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Middle East and Africa acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 9.0% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Middle East and Africa Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing, and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), Monocytic (M5), Erythroleukemia (M6), and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, and 65 and Above), Gender (Male and Female), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Middle East and Africa acute myeloid leukemia diagnostics market are:

A rise in healthcare expenditure for cancer diagnosis and treatment

Novel technological advancements in leukemia diagnostics

Market Players

The key market players in the Middle East and Africa acute myeloid leukemia diagnostics market are listed below:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

QIAGEN

Abbott

Siemens Healthcare GmbH

Merck KGAA

Hologic, Inc.

Agilent Technologies, Inc.

DiaSorin S.p.A.

Illumina, Inc.

BIOMERIEUX

TABLE OF CONTENTS

1 INTRODUCTION 53

  • 1.1 OBJECTIVES OF THE STUDY 53
  • 1.2 MARKET DEFINITION 53
  • 1.3 OVERVIEW OF MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 53
  • 1.4 LIMITATIONS 55
  • 1.5 MARKETS COVERED 56

2 MARKET SEGMENTATION 59

  • 2.1 MARKETS COVERED 59
  • 2.2 GEOGRAPHICAL SCOPE 60
  • 2.3 YEARS CONSIDERED FOR THE STUDY 61
  • 2.4 CURRENCY AND PRICING 61
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
  • 2.6 MULTIVARIATE MODELLING 65
  • 2.7 PRODUCT TYPE LIFELINE CURVE 65
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
  • 2.9 DBMR MARKET POSITION GRID 67
  • 2.10 MARKET END USER COVERAGE GRID 69
  • 2.11 VENDOR SHARE ANALYSIS 70
  • 2.12 SECONDARY SOURCES 71
  • 2.13 ASSUMPTIONS 71

3 EXECUTIVE SUMMARY 72

4 PREMIUM INSIGHTS 75

  • 4.1 PESTEL ANALYSIS 76
  • 4.2 PORTER'S 5 FORCES 77

5 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 78

  • 5.1 REGULATORY SCENARIO IN THE U.S. 78
  • 5.2 REGULATORY SCENARIO IN AUSTRALIA 79
  • 5.3 REGULATORY SCENARIO IN JAPAN 79
  • 5.4 REGULATORY SCENARIO IN CHINA 79

6 MARKET OVERVIEW 81

  • 6.1 DRIVERS 83
    • 6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 83
    • 6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 85
    • 6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 85
    • 6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 86
  • 6.2 RESTRAINTS 87
    • 6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 87
    • 6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 87
  • 6.3 OPPORTUNITIES 88
    • 6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 88
    • 6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 88
    • 6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 89
  • 6.4 CHALLENGES 90
    • 6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 90
    • 6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 90

7 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 91

  • 7.1 OVERVIEW 92
  • 7.2 INSTRUMENTS 95
    • 7.2.1 BIOPSY INSTRUMENTS 96
      • 7.2.1.1 BONE MARROW BIOPSY 96
      • 7.2.1.2 NEEDLE BIOPSY 96
      • 7.2.1.3 SURGICAL BIOPSY 96
      • 7.2.1.4 OTHERS 97
    • 7.2.2 PATHOLOGY-BASED INSTRUMENTS 97
      • 7.2.2.1 PCR INSTRUMENTS 97
      • 7.2.2.2 SLIDE STAINING SYSTEMS 97
      • 7.2.2.3 TISSUE PROCESSING SYSTEMS 97
      • 7.2.2.4 CELL PROCESSORS 97
      • 7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 98
    • 7.2.3 IMAGING INSTRUMENTS 98
      • 7.2.3.1 ULTRASOUND SYSTEMS 98
      • 7.2.3.2 CT SYSTEMS 98
      • 7.2.3.3 MRI SYSTEMS 98
      • 7.2.3.4 OTHERS 98
    • 7.2.4 OTHERS 98
  • 7.3 CONSUMABLES & ACCESSORIES 99
    • 7.3.1 KITS 100
      • 7.3.1.1 PCR KITS 100
      • 7.3.1.2 DNA POLYMERASE KITS 100
      • 7.3.1.3 NUCLEIC ACID ISOLATION KITS 100
      • 7.3.1.4 OTHERS 101
    • 7.3.2 REAGENTS 101
      • 7.3.2.1 ASSAYS 101
      • 7.3.2.2 BUFFERS 101
      • 7.3.2.3 PRIMERS 101
      • 7.3.2.4 OTHERS 101
    • 7.3.3 PROBES 102
    • 7.3.4 OTHER CONSUMABLES 102

8 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 103

  • 8.1 OVERVIEW 104
  • 8.2 BLOOD TEST 107
    • 8.2.1 COMPLETE BLOOD COUNT (CBC) 108
    • 8.2.2 BLOOD CHEMISTRY TESTS 108
    • 8.2.3 OTHERS 108
  • 8.3 IMAGING TEST 108
    • 8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 109
    • 8.3.2 MRI 109
    • 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 110
    • 8.3.4 OTHERS 110
  • 8.4 BONE MARROW TESTS 110
    • 8.4.1 BONE MARROW ASPIRATE 111
    • 8.4.2 BONE MARROW BIOPSY 111
    • 8.4.3 OTHERS 111
  • 8.5 GENETIC TESTS 111
    • 8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 112
    • 8.5.2 KARYOTYPING 112
    • 8.5.3 OTHERS 112
  • 8.6 BIOMARKER TEST 112
    • 8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
    • 8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
    • 8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 114
  • 8.7 IMMUNOPHENOTYPING 114
    • 8.7.1 FLOW CYTOMETRY 115
    • 8.7.2 IMMUNOHISTOCHEMISTRY 115
    • 8.7.3 OTHERS 115
  • 8.8 OTHERS 115

9 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 117

  • 9.1 OVERVIEW 118
  • 9.2 MYELOBLASTIC (M0) 121
  • 9.3 MYELOBLASTIC (M1) 121
  • 9.4 MYELOBLASTIC (M2) 122
  • 9.5 PROMYELOCYTIC (M3) 123
  • 9.6 MYELOMONOCYTIC (M4) 124
  • 9.7 MONOCYTIC (M5) 124
  • 9.8 ERYTHROLEUKEMIA (M6) 125
  • 9.9 MEGAKARYOCYTIC (M7) 126

10 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 127

  • 10.1 OVERVIEW 128
  • 10.2 65 AND ABOVE 131
  • 10.3 30-65 131
  • 10.4 BELOW 21 132
  • 10.5 21-29 133

11 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 135

  • 11.1 OVERVIEW 136
  • 11.2 MALE 139
  • 11.3 FEMALE 139

12 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 141

  • 12.1 OVERVIEW 142
  • 12.2 HOSPITALS 145
  • 12.3 ASSOCIATED LABS 145
  • 12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 146
  • 12.5 DIAGNOSTIC IMAGING CENTERS 147
  • 12.6 CANCER RESEARCH INSTITUTES 147
  • 12.7 OTHERS 148

13 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 150

  • 13.1 OVERVIEW 151
  • 13.2 DIRECT TENDER 154
  • 13.3 RETAIL SALES 154

14 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 156

  • 14.1 MIDDLE EAST AND AFRICA 157
    • 14.1.1 SOUTH AFRICA 169
    • 14.1.2 SAUDI ARABIA 175
    • 14.1.3 UAE 181
    • 14.1.4 EGYPT 187
    • 14.1.5 ISRAEL 193
    • 14.1.6 REST OF MIDDLE EAST AND AFRICA 199

15 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 200

  • 15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 200

16 SWOT ANALYSIS 201

17 COMPANY PROFILE 202

  • 17.1 CANON MEDICAL SYSTEMS CORPORATION. 202
    • 17.1.1 COMPANY SNAPSHOT 202
    • 17.1.2 REVENUE ANALYSIS 202
    • 17.1.3 COMPANY SHARE ANALYSIS 203
    • 17.1.4 PRODUCT PORTFOLIO 203
    • 17.1.5 RECENT DEVELOPMENT 203
  • 17.2 SYSMEX CORPORATION 204
    • 17.2.1 COMPANY SNAPSHOT 204
    • 17.2.2 REVENUE ANALYSIS 204
    • 17.2.3 COMPANY SHARE ANALYSIS 205
    • 17.2.4 PRODUCT PORTFOLIO 205
    • 17.2.5 RECENT DEVELOPMENT 205
  • 17.3 EPIGENOMICS AG. 206
    • 17.3.1 COMPANY SNAPSHOT 206
    • 17.3.2 REVENUE ANALYSIS 206
    • 17.3.3 COMPANY SHARE ANALYSIS 207
    • 17.3.4 PRODUCT PORTFOLIO 207
    • 17.3.5 RECENT DEVELOPMENT 207
  • 17.4 MYRIAD GENETICS, INC
    • 17.4.1 COMPANY SNAPSHOT 208
    • 17.4.2 REVENUE ANALYSIS 208
    • 17.4.3 COMPANY SHARE ANALYSIS 209
    • 17.4.4 PRODUCT PORTFOLIO 209
    • 17.4.5 RECENT DEVELOPMENT 209
  • 17.5 F. HOFFMANN- LA ROCHE LTD 210
    • 17.5.1 COMPANY SNAPSHOT 210
    • 17.5.2 REVENUE ANALYSIS 210
    • 17.5.3 COMPANY SHARE ANALYSIS 211
    • 17.5.4 PRODUCT PORTFOLIO 211
    • 17.5.5 RECENT DEVELOPMENT 211
  • 17.6 ABBOTT 212
    • 17.6.1 COMPANY SNAPSHOT 212
    • 17.6.2 REVENUE ANALYSIS 212
    • 17.6.3 PRODUCT PORTFOLIO 213
    • 17.6.4 RECENT DEVELOPMENT 213
  • 17.7 AGILENT TECHNOLOGIES, INC. 214
    • 17.7.1 COMPANY SNAPSHOT 214
    • 17.7.2 REVENUE ANALYSIS 214
    • 17.7.3 PRODUCT PORTFOLIO 215
    • 17.7.4 RECENT DEVELOPMENT 215
  • 17.8 BD 216
    • 17.8.1 COMPANY SNAPSHOT 216
    • 17.8.2 REVENUE ANALYSIS 216
    • 17.8.3 PRODUCT PORTFOLIO 217
    • 17.8.4 RECENT DEVELOPMENT 217
  • 17.9 BIOMERIEUX 218
    • 17.9.1 COMPANY SNAPSHOT 218
    • 17.9.2 PRODUCT PORTFOLIO 218
    • 17.9.3 RECENT DEVELOPMENT 218
  • 17.10 BIO-RAD LABORATORIES, INC. 219
    • 17.10.1 COMPANY SNAPSHOT 219
    • 17.10.2 REVENUE ANALYSIS 219
    • 17.10.3 PRODUCT PORTFOLIO 220
    • 17.10.4 RECENT DEVELOPMENT 220
  • 17.11 DIASORIN S.P.A. 221
    • 17.11.1 COMPANY SNAPSHOT 221
    • 17.11.2 REVENUE ANALYSIS 221
    • 17.11.3 PRODUCT PORTFOLIO 222
    • 17.11.4 RECENT DEVELOPMENTS 222
  • 17.12 EXACT SCIENCES CORPORATION 223
    • 17.12.1 COMPANY SNAPSHOT 223
    • 17.12.2 REVENUE ANALYSIS 223
    • 17.12.3 PRODUCT PORTFOLIO 224
    • 17.12.4 RECENT DEVELOPMENTS 224
  • 17.13 FONAR CORP. 225
    • 17.13.1 COMPANY SNAPSHOT 225
    • 17.13.2 REVENUE ANALYSIS 225
    • 17.13.3 PRODUCT PORTFOLIO 226
    • 17.13.4 RECENT DEVELOPMENT 226
  • 17.14 HOLOGIC INC. 227
    • 17.14.1 COMPANY SNAPSHOT 227
    • 17.14.2 REVENUE ANALYSIS 227
    • 17.14.3 PRODUCT PORTFOLIO 228
    • 17.14.4 RECENT DEVELOPMENT 228
  • 17.15 ILLUMINA, INC. 229
    • 17.15.1 COMPANY SNAPSHOT 229
    • 17.15.2 REVENUE ANALYSIS 229
    • 17.15.3 PRODUCT PORTFOLIO 230
    • 17.15.4 RECENT DEVELOPMENT 230
  • 17.16 KONINKLIJKE PHILIPS N.V. 231
    • 17.16.1 COMPANY SNAPSHOT 231
    • 17.16.2 REVENUE ANALYSIS 231
    • 17.16.3 PRODUCT PORTFOLIO 232
    • 17.16.4 RECENT DEVELOPMENT 232
  • 17.17 MEDONICA CO. LTD 233
    • 17.17.1 COMPANY SNAPSHOT 233
    • 17.17.2 PRODUCT PORTFOLIO 233
    • 17.17.3 RECENT DEVELOPMENT 233
  • 17.18 MERCK KGAA 234
    • 17.18.1 COMPANY SNAPSHOT 234
    • 17.18.2 REVENUE ANALYSIS 234
    • 17.18.3 PRODUCT PORTFOLIO 235
    • 17.18.4 RECENT DEVELOPMENTS 235
  • 17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 236
    • 17.19.1 COMPANY SNAPSHOT 236
    • 17.19.2 PRODUCT PORTFOLIO 236
    • 17.19.3 RECENT DEVELOPMENT 236
  • 17.20 PLEXBIO 237
    • 17.20.1 COMPANY SNAPSHOT 237
    • 17.20.2 PRODUCT PORTFOLIO 237
    • 17.20.3 RECENT DEVELOPMENTS 237
  • 17.21 QIAGEN 238
    • 17.21.1 COMPANY SNAPSHOT 238
    • 17.21.2 REVENUE ANALYSIS 238
    • 17.21.3 PRODUCT PORTFOLIO 239
    • 17.21.4 RECENT DEVELOPMENTS 239
  • 17.22 QUEST DIAGNOSTICS INCORPORATED 240
    • 17.22.1 COMPANY SNAPSHOT 240
    • 17.22.2 REVENUE ANALYSIS 240
    • 17.22.3 PRODUCT PORTFOLIO 241
    • 17.22.4 RECENT DEVELOPMENTS 241
  • 17.23 SIEMENS HEALTHCARE GMBH 242
    • 17.23.1 COMPANY SNAPSHOT 242
    • 17.23.2 REVENUE ANALYSIS 242
    • 17.23.3 PRODUCT PORTFOLIO 243
    • 17.23.4 RECENT DEVELOPMENT 243
  • 17.24 SONIC HEALTHCARE 244
    • 17.24.1 COMPANY SNAPSHOT 244
    • 17.24.2 PRODUCT PORTFOLIO 244
    • 17.24.3 RECENT DEVELOPMENT 244
  • 17.25 STERNMED GMBH 245
    • 17.25.1 COMPANY SNAPSHOT 245
    • 17.25.2 PRODUCT PORTFOLIO 245
    • 17.25.3 RECENT DEVELOPMENTS 245
  • 17.26 THERMO FISHER SCIENTIFIC INC. 246
    • 17.26.1 COMPANY SNAPSHOT 246
    • 17.26.2 REVENUE ANALYSIS 246
    • 17.26.3 PRODUCT PORTFOLIO 247
    • 17.26.4 RECENT DEVELOPMENT 247
  • 17.27 TIME MEDICAL HOLDING 248
    • 17.27.1 COMPANY SNAPSHOT 248
    • 17.27.2 PRODUCT PORTFOLIO 248
    • 17.27.3 RECENT DEVELOPMENT 248

18 QUESTIONNAIRE 249

19 RELATED REPORTS 253

LIST OF TABLES

  • TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 59
  • TABLE 2 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65
  • TABLE 3 MIDDLE EAST & AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 66
  • TABLE 4 MIDDLE EAST & AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 67
  • TABLE 5 MIDDLE EAST & AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 67
  • TABLE 6 MIDDLE EAST & AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 68
  • TABLE 7 MIDDLE EAST & AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 69
  • TABLE 8 MIDDLE EAST & AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
  • TABLE 9 MIDDLE EAST & AFRICA CONSUMABLES AND ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 71
  • TABLE 10 MIDDLE EAST & AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 71
  • TABLE 11 MIDDLE EAST & AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 72
  • TABLE 12 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 77
  • TABLE 13 MIDDLE EAST & AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 78
  • TABLE 14 MIDDLE EAST & AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 79
  • TABLE 15 MIDDLE EAST & AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
  • TABLE 16 MIDDLE EAST & AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 80
  • TABLE 17 MIDDLE EAST & AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
  • TABLE 18 MIDDLE EAST & AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 82
  • TABLE 19 MIDDLE EAST & AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 20 MIDDLE EAST & AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 83
  • TABLE 21 MIDDLE EAST & AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 22 MIDDLE EAST & AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 84
  • TABLE 23 MIDDLE EAST & AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
  • TABLE 24 MIDDLE EAST & AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 85
  • TABLE 25 MIDDLE EAST & AFRICA OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
  • TABLE 26 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 91
  • TABLE 27 MIDDLE EAST & AFRICA MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
  • TABLE 28 MIDDLE EAST & AFRICA MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 93
  • TABLE 29 MIDDLE EAST & AFRICA MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 94
  • TABLE 30 MIDDLE EAST & AFRICA PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 94
  • TABLE 31 MIDDLE EAST & AFRICA MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
  • TABLE 32 MIDDLE EAST & AFRICA MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
  • TABLE 33 MIDDLE EAST & AFRICA ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
  • TABLE 34 MIDDLE EAST & AFRICA MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
  • TABLE 35 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 101
  • TABLE 36 MIDDLE EAST & AFRICA 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
  • TABLE 37 MIDDLE EAST & AFRICA 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
  • TABLE 38 MIDDLE EAST & AFRICA BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
  • TABLE 39 MIDDLE EAST & AFRICA 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
  • TABLE 40 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 109
  • TABLE 41 MIDDLE EAST & AFRICA MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
  • TABLE 42 MIDDLE EAST & AFRICA FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
  • TABLE 43 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 115
  • TABLE 44 MIDDLE EAST & AFRICA HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
  • TABLE 45 MIDDLE EAST & AFRICA ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 117
  • TABLE 46 MIDDLE EAST & AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 117
  • TABLE 47 MIDDLE EAST & AFRICA DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
  • TABLE 48 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
  • TABLE 49 MIDDLE EAST & AFRICA OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
  • TABLE 50 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 124
  • TABLE 51 MIDDLE EAST & AFRICA DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 125
  • TABLE 52 MIDDLE EAST & AFRICA RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
  • TABLE 53 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 133
  • TABLE 54 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 55 MIDDLE EAST AND AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 56 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 57 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 58 MIDDLE EAST AND AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 59 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 60 MIDDLE EAST AND AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 61 MIDDLE EAST AND AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 62 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
  • TABLE 63 MIDDLE EAST AND AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
  • TABLE 64 MIDDLE EAST AND AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
  • TABLE 65 MIDDLE EAST AND AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 66 MIDDLE EAST AND AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 67 MIDDLE EAST AND AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 68 MIDDLE EAST AND AFRICA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 69 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 70 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 138
  • TABLE 71 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 138
  • TABLE 72 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 139
  • TABLE 73 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 139
  • TABLE 74 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 75 SOUTH AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 76 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 77 SOUTH AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 78 SOUTH AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 79 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 80 SOUTH AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 81 SOUTH AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 142
  • TABLE 82 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
  • TABLE 83 SOUTH AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
  • TABLE 84 SOUTH AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 85 SOUTH AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 86 SOUTH AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 87 SOUTH AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 88 SOUTH AFRICA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 89 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 90 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 144
  • TABLE 91 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 145
  • TABLE 92 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 145
  • TABLE 93 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 145
  • TABLE 94 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 95 SAUDI ARABIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 96 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 97 SAUDI ARABIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 98 SAUDI ARABIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 99 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 100 SAUDI ARABIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 101 SAUDI ARABIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 102 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 103 SAUDI ARABIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 104 SAUDI ARABIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 105 SAUDI ARABIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 106 SAUDI ARABIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 107 SAUDI ARABIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 108 SAUDI ARABIA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 109 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 110 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 151
  • TABLE 111 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 151
  • TABLE 112 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 151
  • TABLE 113 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 151
  • TABLE 114 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 115 UAE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 116 UAE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 117 UAE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 118 UAE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 119 UAE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 120 UAE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 121 UAE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 122 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 123 UAE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 124 UAE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 125 UAE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 126 UAE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 127 UAE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 128 UAE GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 129 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 130 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 157
  • TABLE 131 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 157
  • TABLE 132 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 157
  • TABLE 133 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 157
  • TABLE 134 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 135 EGYPT INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION 29
  • FIGURE 2 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DATA TRIANGULATION 32
  • FIGURE 3 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DROC ANALYSIS 33
  • FIGURE 4 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 34
  • FIGURE 5 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS 34
  • FIGURE 6 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS 36
  • FIGURE 7 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 37
  • FIGURE 8 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : MARKET END USER COVERAGE GRID 39
  • FIGURE 9 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS 40
  • FIGURE 10 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION 44
  • FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD 45
  • FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2023 & 2030 45
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 52
  • FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 54
  • FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 54
  • FIGURE 16 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 62
  • FIGURE 17 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 63
  • FIGURE 18 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 63
  • FIGURE 19 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 64
  • FIGURE 20 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2022 74
  • FIGURE 21 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 75
  • FIGURE 22 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 75
  • FIGURE 23 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 76
  • FIGURE 24 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 88
  • FIGURE 25 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 89
  • FIGURE 26 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 89
  • FIGURE 27 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 90
  • FIGURE 28 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2022 98
  • FIGURE 29 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 99
  • FIGURE 30 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 99
  • FIGURE 31 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 100
  • FIGURE 32 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2022 106
  • FIGURE 33 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 107
  • FIGURE 34 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 107
  • FIGURE 35 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 108
  • FIGURE 36 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2022 112
  • FIGURE 37 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 113
  • FIGURE 38 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 113
  • FIGURE 39 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 114
  • FIGURE 40 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 121
  • FIGURE 41 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 122
  • FIGURE 42 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 122
  • FIGURE 43 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 123
  • FIGURE 44 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2022) 128
  • FIGURE 45 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022) 130
  • FIGURE 46 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 130
  • FIGURE 47 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 131
  • FIGURE 48 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 131
  • FIGURE 49 MIDDLE EAST & AFRICA Acute myeloid leukemia Diagnostics market: COMPANY SHARE 2022 (%) 170
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!